The Brazilian Ministry of Health has announced the gradual addition of three drugs for the treatment of lung cancer in the public health system. The treatments brigatinib and gefitinib, which can be administered at home, as well as the immunotherapy durvalumab, aim to improve access to care for patients. This initiative is part of a broader strategy to expand the available oncological treatments.